国联民生证券承销保荐有限公司（以下简称"保荐机构"）作为碧兴物联科 技（深圳）股份有限公司（以下简称"碧兴物联"、"公司"）首次公开发行股 票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海 证券交易所科创板上市公司自律监管指引第1号——规范运作》和《上市公司募集 资金监管规则》等法律法规有关规定，对碧兴物联使用自有资金支付募投项目所 需资金并以募集资金等额置换的事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意碧兴物联科技（深圳）股份有限公司 首次公开发行股票注册的批复》（证监许可[2023]1009号）同意注册，公司首次公 开发行人民币普通股（A股）19,630,000.00股，每股发行价格36.12元，募集资金总 额为人民币709,035,600.00元，扣除不含税发行费用人民币85,592,015.58元，实际募 集资金净额为人民币623,443,584.42元，该募集资金已于2023年8月4日到账。上述 募集资金到位情况已经立信会计师事务所（特殊普通合伙）审验，并出具了信会 师报字[2023]第ZL10015号验资报告。 二、募集资金投资项目 ...

证券代码：601456 证券简称：国联民生 公告编号：2025-055 号 国联民生证券股份有限公司 关于子公司重大诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 原告：李立群等 1,618 名投资者（投资者人数已经济南中院审查确认） 代表人：李立群、万云、孙静、田庆龙、李明臣 被告：龙力生物、程少博等 12 名自然人、国联民生承销保荐、立信会计师 事务所（特殊普通合伙）（以下简称"立信会计"） 案由：证券虚假陈述责任纠纷 诉讼方式：普通代表人诉讼 公司分别于 2022 年 8 月 6 日披露了《关于子公司重大诉讼的公告》（公告编 1 案件所处的诉讼阶段：一审判决 上市公司所处的当事人地位：国联民生证券股份有限公司（以下简称 "公司"）全资子公司国联民生证券承销保荐有限公司（以下简称"国 联民生承销保荐"，曾用名：华英证券有限责任公司）为 15 名被告之 一。 涉案的金额：一审判决原告及原告代表人对被告山东龙力生物科技股 份有限公司（以下简称"龙力生物"）享有投资差额损失、通知费及律 师费债权数 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （股份代號：01456） （於中華人民共和國成立的股份有限公司） 關於子公司重大訴訟的進展公告 近日，國聯民生承銷保薦收到山東省濟南市中級人民法院（「濟南中院」或「本院」）送 達的《民事判決書》，現將相關信息公告如下： 一、訴訟的基本情况 1 原告： 李立群等1,618名投資者（投資者人數已經濟南中院審查確認） 代表人： 李立群、萬雲、孫靜、田慶龍、李明臣 被告： 山東龍力生物科技股份有限公司（「龍力生物」）、程少博等12名 自然人、國聯民生承銷保薦、立信會計師事務所（特殊普通合夥） （「立信會計」） 案由： 證券虛假陳述責任糾紛 訴訟方式： 普通代表人訴訟 二、原告訴訟請求、事實和理由 （一）原告訴訟請求 （二）訴訟事實和理由 原告訴稱，因龍力生物的虛假陳述行為，中國證券監督管理委員會對龍力 生物等主體作出相應處罰。各原告在相關期間買入並持有龍力生物股票的 損失與龍力生物虛假陳述行為之間存在因果關係。 ...

Product Prices and Market Performance - Overall demand has decreased due to the pharmaceutical environment, but the three main intermediate products of the company have shown varied performance. The price of thiocyanate erythromycin has risen slightly, with a single-digit increase since the beginning of the year, and is expected to remain stable in the second half of the year. The price of cephalosporin products is stable and is expected to maintain the current situation in the second half. The price of penicillin has decreased since the beginning of the year, but with increasing industry concentration, it is becoming more difficult for small companies to enter the market. An increase in demand is expected in the fourth quarter, which may improve the situation [1]. Synthetic Biology and Project Progress - Sales of synthetic biology products are steadily advancing, with the company achieving a revenue of 22.32 million yuan in the first half of the year. With adjustments and releases in production capacity, future sales are expected to increase. The methanol protein project has undergone trials in a 30m³ fermentation tank, with initial results available and samples sent to downstream manufacturers for testing. The company is also actively applying for qualifications from the Ministry of Agriculture and Rural Affairs [2]. Overseas Capacity and Domestic Planning - After assessment, the company has decided to postpone its entry into Kazakhstan due to several uncontrollable risks. The first phase of the company is in a rapid development stage, and the second phase will be determined based on the R&D progress of the Shanghai Research Institute and the release of first-phase capacity [3]. Order Expectations and Capital Expenditure - The company anticipates growth in orders with Kelun Yongnian Company for ergotamine. There are no significant capital expenditures expected in the short term, with fixed asset depreciation for the first half of 2025 amounting to 273 million yuan, an increase of 22 million yuan year-on-year. Starting in 2026, the main equipment depreciation is expected to decrease significantly, with a projected reduction of tens of millions if no new fixed assets are added by the end of 2027 [4]. R&D and Product Selection Planning - Future R&D will focus on four main areas: traditional product synthesis and biological modification; technology enhancement and cost reduction for delivered products; efficient biological utilization of C1/C2 resources; and the development of amino acids and vitamin products [5]. Cost Trends and Import-Export Situation - The price of the main raw material, corn, is expected to rise to 1.8 - 1.9 yuan/kg in November. Energy costs, particularly coal prices, have decreased compared to 2024 and are expected to remain stable in the coming years. The export amount has increased by approximately 25% compared to the same period last year, mainly due to increased exports of thiocyanate and 6-APA, while cephalosporin exports have slightly decreased. Exports are primarily directed towards India and Hong Kong, with tariffs having minimal impact on the company's exports [6]. Gross Margin and Production Efficiency - With the increase in synthetic biology product volume and the application of AI technology, the company has room for improvement in gross margin. AI-controlled fermentation tank output exceeds the control group by 3% - 5%, reducing production fluctuations and enhancing R&D efficiency. The overall gross margin for the company in the first half of 2025 was 35.90%, a year-on-year increase of 0.55%, while the gross margin for pharmaceutical intermediates was 38.64%, a year-on-year increase of 1.37% [7]. Expenses and Performance Outlook - The sales expense ratio for the first half of 2025 was 0.58%, an increase of 0.21% year-on-year, and is expected to remain stable in the second half. The management expense ratio was 3.37%, an increase of 0.13% year-on-year, while the financial expense ratio was 0.67%, a decrease of 0.19% year-on-year. The company is facing performance pressure this year due to the impact of penicillin prices, with expectations of a decline compared to last year. However, in 2026, with the increase in synthetic biology product volume and the recovery of penicillin prices, performance and profits are expected to improve [8].

双元科技首次公开发行股票募集资金总额186,122.39万元，扣除发行费用后募集资金净额为166,635.87万 元。双元科技实际募资净额比原拟募资多101,478.09万元。双元科技于2023年6月2日披露的招股说明书 显示，该公司拟募集资金65,157.78万元，用于智能测控装备生产基地项目、研发中心项目、营销网络及 技术支持中心建设项目、补充流动资金。 双元科技保荐机构为民生证券股份有限公司(现为国联民生（601456）证券股份有限公司)，保荐代表人 为王艺霖、袁莉敏。双元科技首次公开发行股票的发行费用总额为19,486.52万元，其中民生证券股份有 限公司获得保荐费及承销费用17,071.92万元。 中国经济网北京8月26日讯双元科技(688623.SH)今日收报68.72元，跌幅3.40%，总市值40.64亿元。目前 该股处于破发状态。 双元科技于2023年6月8日在上交所科创板上市，本次发行数量为1,478.5700万股，发行价格为125.88元/ 股。 上市首日，该股创下股价高点120.00元，此后股价震荡下跌。 根据双元科技发布的首次公开发行股票科创板上市公告书，该公司发行的战略配售为保荐人相 ...

Core Viewpoint - The report highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies, which may signal potential investment opportunities or shifts in market sentiment. Group 1: Increased Holdings - Shandong Molong (00568) saw the largest increase in Hong Kong Stock Connect holdings, rising by 3.41% to a total holding of 58.38% [2] - ZTE Corporation (00763) experienced a 2.52% increase, bringing its holding to 54.86% [2] - Lens Technology (06613) increased by 2.22%, with a current holding of 11.01% [2] - Other notable increases include Southern Hang Seng Technology (03033) at +2.08% (60.66%) and Beijing Jingcheng Machinery Electric Company (00187) at +1.35% (49.54%) [2] Group 2: Decreased Holdings - Hang Seng China Enterprises (02828) had the largest decrease, down by 2.31% to 1.02% [2] - The Tracker Fund of Hong Kong (02800) decreased by 0.74%, now holding 1.87% [2] - Li Jin Technology (00558) saw a reduction of 0.69%, with a holding of 14.36% [2] - Other significant decreases include Ping An Good Doctor (01833) at -0.65% (19.25%) and Beijing North Star Company (00588) at -0.59% (41.42%) [2] Group 3: Five-Day Changes - Over the last five trading days, ZTE Corporation (00763) had the highest increase in holdings at +7.26% (54.86%) [3] - Longpan Technology (02465) increased by 6.03% to 51.76% [3] - Tongyuan Kang Pharmaceutical-B (02410) rose by 5.38%, now at 14.68% [3] - Significant decreases included Dongyang Sunshine Pharmaceutical (06887) at -3.85% (44.05%) and Zhejiang Shibao (01057) at -2.73% (55.74%) [3] Group 4: Twenty-Day Changes - Longfei Optical Fiber and Cable (06869) had the largest increase over twenty days at +22.04% (56.07%) [4] - Meizhong Jiahe (02453) increased by 12.55% to 37.75% [4] - Other notable increases include Yimai Sunshine (02522) at +11.66% (40.40%) and Kanglong Chemical (03759) at +9.51% (59.33%) [4] - Decreases over twenty days included Chongqing Steel (01053) at -5.91% (32.47%) and Dongfang Electric (01072) at -5.60% (37.80%) [4]

证券日报网讯 8月25日晚间，国联民生发布公告称，近日，国联民生证券股份有限公司全资子公司国联 民生证券承销保荐有限公司完成法定代表人变更登记手续，其法定代表人由葛小波变更为徐春，并取得 了上海市市场监督管理局换发的营业执照。 （文章来源：证券日报） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （股份代號：01456） （於中華人民共和國成立的股份有限公司） 海外監管公告 本公告乃根據《香港聯合交易所有限公司證券上市規則》第13.10B條作出。 如下公告已於上海證券交易所網站刊發，僅供參閱。 特此公告。 承董事會命 國聯民生證券股份有限公司 董事長 顧偉 中國江蘇省無錫市 2025年8月25日 截至本公告日期，本公司執行董事為葛小波先生；本公司非執行董事為顧偉先生、 周衛平先生、吳衛華先生、楊振興先生及劉海林先生；及本公司獨立非執行董事為 高偉先生、郭春明先生及徐慧敏女士。 证券代码：601456 证券简称：国联民生 公告编号：2025-054 号 国联民生证券股份有限公司 关于子公司完成法定代表人工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，国联民生证券股份有限公司全资子公司国联民 ...

关于子公司完成法定代表人工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，国联民生证券股份有限公司全资子公司国联民生证券承销保荐有限公 司完成法定代表人变更登记手续，其法定代表人由葛小波变更为徐春，并取得了 上海市市场监督管理局换发的营业执照，相关登记信息如下： 证券代码：601456 证券简称：国联民生 公告编号：2025-054 号 国联民生证券股份有限公司 统一社会信用代码：91320214717884755C 名称：国联民生证券承销保荐有限公司 类型：有限责任公司（非自然人投资或控股的法人独资） 住所：中国（上海）自由贸易试验区浦明路 8 号 特此公告。 国联民生证券股份有限公司董事会 2025 年 8 月 25 日 1 注册资本：人民币 20,000 万元整 成立日期：2011 年 04 月 20 日 经营范围：许可项目：证券业务；债券市场业务。（依法须经批准的项目， 经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可 证件为准）一般项目：证券财务顾问服务。（除依法须经批准 ...

Group 1 - The article highlights the top three companies with the highest AH premium rates as Northeast Electric (00042) at 743.75%, Hongye Futures (03678) at 241.98%, and Andeli Juice (02218) at 236.37% [1] - The bottom three companies with the lowest AH premium rates include Ningde Times (03750) at -16.43%, Heng Rui Medicine (01276) at 1.82%, and Midea Group (00300) at 4.90% [1] - The article provides a detailed table of the top ten and bottom ten AH stocks based on premium rates and deviation values, indicating significant disparities in market valuations between H-shares and A-shares [1][2] Group 2 - The deviation values for the top three companies are Andeli Juice (02218) at 32.29%, Jinli Permanent Magnet (06680) at 22.19%, and Beijing Machinery (00187) at 20.80% [1] - The companies with the lowest deviation values include BYD Company (01211) at -98.36%, Northeast Electric (00042) at -64.84%, and Longpan Technology (02465) at -51.92% [1][2] - The article emphasizes that the deviation value represents the difference between the current premium rate and the average premium rate over the past 30 days, providing insights into market trends [2]